Skip to main content

Volume 3 Supplement 2

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression

Purpose

Immunotherapies aiming to interfere with the immune checkpoint molecule PD-1 (programmed death-1) and its ligand PD-L1 are currently being investigated in several clinical trials to treat cancer patients. Little is known about the effect of age or cancer on peripheral immune cell subsets or on their expression of PD-1 and PD-L1. The aim of this study was to assess the differences in immune cell subsets, focusing on PD-1 and PD-L1 expression, between young and old healthy donors, as well as between age-matched healthy donors and cancer patients.

Methods

A total of 123 peripheral immune cell subsets were analyzed by flow-cytometry using 30 unique markers. The subsets included 9 standard subsets (CD4 and CD8 T cells, regulatory T cells (Treg), B cells, conventional dendritic cells (cDC), plasmacytoid DC (pDC), natural killer cells (NK), natural killer T cells (NKT), and myeloid derived suppressor cell (MDSC)), and 114 subsets relating to maturation and function. PD-1 and PD-L1 surface expression was analyzed in all relevant subsets. The frequency of immune cells were compared between young (under age 40, n=11) and old (over age 40, n=15) apparently healthy individuals to assess the effect of age. To investigate the effect of cancer, the older healthy individuals were also compared to age matched patients with several types of advanced cancer (over age 40, n=30).

Results

Compared to young healthy individuals, older subjects had several notable differences, including lower levels of total CD8 T cells and naïve CD8 T cells, and higher levels of total NK cells and PD-1 positive CD4 T cells. Relative to age-matched healthy individuals, advanced cancer patients had noteworthy differences in several immune cell subsets, such as higher levels of total CD8 T cells and PD-L1 positive MDSC, and lower levels of total B cells and PD-L1 positive B cells.

Conclusions

The frequencies of several peripheral immune cell subsets, including some that express PD-1 or PD-L1, are affected by both age and cancer.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Renee Donahue.

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Grenga, I., Lepone, L., Donahue, R. et al. Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression. j. immunotherapy cancer 3, P253 (2015). https://doi.org/10.1186/2051-1426-3-S2-P253

Download citation

Keywords

  • Immune Checkpoint
  • Myeloid Derive Suppressor Cell
  • Immune Cell Subset
  • Treat Cancer Patient
  • Young Healthy Individual